No Clinically Significant Drug-Resistance Mutations in HIV-1 Subtype C–Infected Women After Discontinuation of NRTI-Based or PI-Based HAART for PMTCT in Botswana

• DOI: 10.1097/qai.0b013e31829308f8
• Publication Date: 2013-03-29T12:27:26Z
• Authors: Sajini Souda; Simani Gaseitsiwe; Nathan Georgette; Kathleen Powis; Daisy Moremedi; Thato Iketleng; Jean Leidner; Claire Moffat; Anthony Ogwu; Shahin Lockman; Sikhulile Moyo; Mompati Mmalane; Rosemary Musonda; Joseph Makhema; Max Essex; Roger Shapiro
• Keywords: Lopinavir; Discontinuation; Abacavir; Ritonavir; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Nelfinavir; Stavudine

Risk of developing drug resistance after stopping antiretroviral regimens to prevent mother-to-child HIV-1 transmission is unknown. The Mma Bana Study randomized treatment-naive pregnant women with CD4 ≥200 cells per cubic millimeter receive either abacavir/zidovudine/lamivudine [triple nucleoside reverse transcriptase inhibitor (NRTI) arm] or lopinavir/ritonavir/zidovudine/lamivudine [protease (PI) arm]. Drugs were discontinued 6 months breastfeeding. One month discontinuation, 29 NRTI arm samples and 25 PI successfully genotyped. No clinically significant mutations detected. Eight minor found among 11 (20%) (3 from 8 arm), occurring at similar frequencies those reported in subtype C cohorts.